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Intracellular granules in several types of leukocytes contain pre-
formed proteins whose secretions contribute to immune and
inflammatory functions of leukocytes, including eosinophils, cells
notably associated with asthma, allergic inflammation, and hel-
minthic infections. Cytokines and chemokines typically elicit ex-
tracellular secretion of granule proteins by engaging receptors
expressed externally on the plasma membranes of cells, including
eosinophils. Eosinophil granules, in addition to being intracellular
organelles, are found as intact membrane-bound structures extra-
cellularly in tissue sites of eosinophil-associated diseases. Neither
the secretory capacities of cell-free eosinophil granules nor the
presence of functional cytokine and chemokine receptors on mem-
branes of leukocyte granules have been recognized. Here, we
show that granules of human eosinophils express membrane
receptors for a cytokine, IFN-, and G protein–coupled membrane
receptors for a chemokine, eotaxin, and that these receptors
function by activating signal-transducing pathways within gran-
ules to elicit secretion from within granules. Capacities of intra-
cellular granule organelles to function autonomously outside of
eosinophils as independent, ligand-responsive, secretion-competent
structures constitute a novel postcytolytic mechanism for regulated
secretion of eosinophil granule proteins that may contribute to
eosinophil-mediated inflammation and immunomodulation.
allergy  specific  eotaxin  IFN-
Human eosinophils, leukocytes notably associated with aller-gic, anthelminthic parasite, and other immune responses
(1–3), contain an abundance of large cytoplasmic granules
ultrastructurally unique because of their internal crystalline
cores. As intracellular organelles, these granules are central to
the functional responses of eosinophils in that granules house
preformed stores of (i) four major cationic proteins, including
eosinophil cationic protein (ECP), major basic protein (MBP),
and eosinophil peroxidase (EPO); (ii) hydrolytic enzymes; and
(iii) more than 30 cytokines, chemokines, and growth factors (3,
4). The extracellular release of these diverse granule proteins
may occur, at times, by exocytosis mediated by fusion of granules
with the plasma membrane, a process mobilizing the entire
protein repertoire of granules. Alternatively, eosinophil secre-
tion more often involves an intracellular process of piecemeal
degranulation, whereby granule proteins are mobilized and
transported in secretory vesicles for extracellular release from
intact eosinophils (4). Piecemeal degranulation results in the
selective secretion of granule-derived proteins and is initiated by
ligands (e.g., IFN-) (5) and eotaxin (also called CCL11) (6),
acting via their cognate plasma membrane-expressed receptors.
A third, as yet, enigmatic mode of eosinophil degranulation
arises from cytolysis of eosinophils that deposits intact mem-
brane-bound eosinophil granules extracellularly (7). With their
unique ultrastructure, free extracellular eosinophil granules
have been recognized in the airways or tissues in association with
diverse disorders, including allergic asthma and rhinitis, derma-
titis, helminth infections, eosinophilic esophagitis, and urticaria
(7–12). Neither functional roles nor consequences of cell-free
extracellular eosinophil granules have been delineated. Here, we
evaluated the capacity of eosinophil granules to function extra-
cellularly as secretory organelles. These investigations were
engendered by recent findings. First, intracellular eosinophil
granules contain substantial quantities of chemokine and cyto-
kine receptors (13). Second, upon eosinophil stimulation, vesi-
cles arise, in a brefeldin A (BFA)–inhibitable process, from
tubular membranes within granules transporting granule cyto-
kines and cationic proteins (13–15). We found that cell-free
eosinophil granules respond to IFN- and eotaxin stimuli via
cognate granule membrane-expressed receptors, topologically
oriented to respond to cytokine and chemokine proteins acting
externally upon granule membranes. Both IFN- and eotaxin
activate intragranular signaling pathways and BFA-inhibitable
secretory mechanisms to elicit secretion of granule-derived
enzymes, cytokines, and cationic proteins.
Results
Subcellular Isolation and Characterization of Purified Eosinophil Gran-
ules. We studied the secretory responses of cell-free granules
isolated by density gradient subcellular fractionation from hu-
man eosinophils, finding that denser granule-enriched fractions
were distinct from buoyant secretory vesicles [supporting infor-
mation (SI) Fig. S1A]. By flow cytometry, isolated granules
contained immunoreactive MBP following membrane perme-
abilization (Fig. S1B) and were devoid of contaminating plasma
membrane MHC class I protein expression (Fig. S1C). By
transmission electron microscopy (TEM), purified granules ex-
hibited intact surrounding membranes (Fig. S1D). Isolated gran-
ules expressed lysosome-associated membrane proteins
(LAMP)-2 (Fig. S1E) and -3 (CD63) (Fig. S1F) previously
localized to eosinophil granules (16, 17). Like granules in intact
eosinophils (Fig. S1Gi), isolated granules stained with lysoso-
motropic acridine orange (AO) (Fig. S1Gii).
Eosinophil Granules Function as Cell-Free Secretion-Competent Or-
ganelles in Response to IFN- and Eotaxin. The presence of free
extracellular eosinophil granules has been recognized in vivo in
tissues in association with diverse eosinophilic disorders (Fig. 1;
refs. 7–12), but potential functional roles of their deposition have
not been delineated. Granules isolated by subcellular fraction-
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ation, in response to stimulation with the cytokine IFN- and the
chemokine eotaxin, dose dependently released ECP (Fig. 2A).
Secretion of 0.5%–2% (m/m) of granule ECP (Fig. S2A) was
rapid, starting within 5 min and reaching plateau values by 30
min (Fig. S2B). Likewise, both stimuli elicited secretion of
granule-derived -hexosaminidase and EPO (Fig. S2C). The
release of sequestered AO from organelles generates a fluores-
cent green ‘‘f lash’’ attributable to release of monomeric AO at
neutral pH (18). To ascertain that isolated granules were the
organelles responsive to agonists, we demonstrated that AO-
loaded granules, in response to IFN- and eotaxin stimulation
(Fig. 2B, Movie S1, and Movie S2), exhibited activation, as
evidenced by intense fluorescent flashes attributable to granule
release of AO.
To assess whether IFN- and eotaxin acted via granule
membrane-expressed receptors, we analyzed by flow cytometry
the expression and topology of receptor proteins for these two
agonists. Cell-free granules without membrane permeabilization
exhibited staining for IFN- receptors (IFN-R) using a mAb
specific for the ‘‘extracellular’’ region of the IFN-R  chain
(Fig. 3A). Likewise, Ab to the extracellular ligand-binding region
of the G protein–coupled CCR3 receptor for eotaxin (Fig. 3B)
detected CCR3 expression on isolated granules, whereas stain-
ing with a polyclonal Ab (pAb) to the ‘‘intracellular’’ carboxy-
terminal domain of CCR3 was negative (Fig. 3C) on nonper-
meabilized granules. To confirm that the association of CCR3
with isolated granules was not an artifact of subcellular frac-
tionation, eosinophils were incubated with plasma-coated
Sepharose beads, an interaction that elicits eosinophil activation
and cytolytic granule release (19). Granules cytolytically ex-
truded from eosinophils likewise expressed extracellular do-
mains of CCR3 on granule membranes (Fig. S3) and, following
AO loading, responded to eotaxin stimulation with intense
fluorescent flashes of released AO (Movie S3). Thus, granule
membranes expressed two structurally distinct receptors, the
heterodimeric IFN-R and the heptahelical G protein–coupled
receptor (GPCR) CCR3, both of which exhibited external
ligand-binding orientations typical of extracellular domains,
despite arising from an intracellular cytosolic milieu.
IFN-– and Eotaxin-Elicited ECP Secretion Is Mediated by Intragranule
Signaling Pathways. We evaluated signaling pathways within
cell-free eosinophil granules that coupled IFN-R– and CCR3-
initiated signaling to granule secretion. Genistein, a tyrosine
kinase inhibitor, dose dependently inhibited ECP release from
IFN-–stimulated granules (Fig. 4A). IFN-–induced ECP re-
lease was also dose dependently inhibited by SB203580 and
SB202190, both p38 MAPK inhibitors (Fig. 4B), and by calphos-
tin C, a likely PKC blocker (Fig. 4C). In contrast, LY2924002, a
PI3K inhibitor, did not inhibit IFN-–stimulated ECP secretion
from granules (Fig. 4D). Likewise, eotaxin-initiated signaling
within isolated granules was evaluated. Pertussis toxin, an in-
hibitor of Gi/o type G proteins, dose dependently inhibited
eotaxin-elicited secretion of ECP (Fig. 4E), compatible with
eotaxin acting via its Gi/o protein-coupled CCR3, GPCR. The
p38 MAPK inhibitors, SB203580 and SB202190 (Fig. 4F), the
PKC inhibitor, calphostin C (Fig. 4G), and the PI3K inhibitor,
LY2924002 (Fig. 4H), dose dependently inhibited eotaxin-
stimulated ECP secretion from eosinophil granules. Moreover,
isolated granules contained signaling PKC and p38 MAPK (Fig.
4I). Eotaxin stimulation of granules elicited the activation-
associated phosphorylation of granule and eosinophil p38
MAPK (Fig. 4J). Furthermore IFN- stimulation of granules
induced phosphorylation of tyrosine residues in a protein with
the predicted molecular weight for the IFN- R  chain. The
phosphorylation was inhibited by preincubation of granules with
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Fig. 1. Extracellular eosinophil granules are recognized in tissues in associ-
ationwith diverse disorders. (A) Extracellular eosinophil granules (arrows) are
present in a skin lesion of a subject with hypereosinophilic syndrome. (Scale
bar: 1m.) (B) Cell-free eosinophil granules (arrowheadandhighermagnified
in Bi) and intact eosinophils (arrows and higher magnified in Bii) were iden-
tified in a skin biopsy of a patient with verrucous cancer. Preparations were
stainedwithH&E and examined by lightmicroscopy. [Scale bar: 17m, 3.6m
(Bi), and 6 m (Bii).]
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Fig. 2. Extracellular eosinophil granules function as cell-free secretion-
competent organelles in response to IFN- and eotaxin. (A) Eosinophil gran-
ules secrete ECP in response to IFN- (solid line and squares) and eotaxin
(dashed line and solid triangles). Secreted ECP levels, means of duplicates 
SD, are ECP levels from stimulated granules minus ECP levels from unstimu-
lated granules, as assayed after 1 h by ELISA. Data from one experiment are
representative of three, each of which demonstrated significant dose-
dependent secretion elicited by eotaxin and IFN- (by ANOVA). *P  0.05 vs.
IFN 1-ng/ml stimulated samples. (B) AO loaded granules (arrows) respond 0,
10, 13, 32, 35, and 92 sec after IFN- stimulation with intense transient
fluorescent flashes indicative of release of monomeric AO. Fluorescence in-
tensity is pseudocolored, with red representing the greatest intensity as
indicated by the scale color. (Scale bar: 3 m.)
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genistein (Fig. 4K). These findings provide direct evidence that
granule membrane receptors are functional and able to initiate
signaling. Thus, although the two receptor-initiated secretory
responses of cell-free eosinophil granules differed in their reli-
ance on PI3K-mediated signaling, both granule secretory re-
sponses were dependent on specific signaling transducing path-
ways within granules.
BFA Inhibits Secretion from IFN-– and Eotaxin-Stimulated Eosinophil
Granules. We previously demonstrated that intracellular eosino-
phil granules containmembranous vesiculotubular networks that
contribute to forming secretory vesicles within granules (14, 15).
BFA inhibits vesicular transport-mediated piecemeal degranu-
lation by eosinophils; and one site of BFA’s inhibitory action is
within granules, as evidenced by BFA inducing the collapse of
intragranular vesiculotubular membranes into membranolipid
deposits recognized by TEM (14). We evaluated whether BFA
had similar effects on stimulated secretion from isolated eosin-
ophil granules. BFA dose dependently inhibited IFN-– (Fig.
5A) and eotaxin- (Fig. 5B) elicited ECP secretion and inhibited
eotaxin-elicited -hex (Fig. S4) secretion from cell-free granules.
Moreover, as assessed by TEM, BFA treatment of isolated
IFN-–stimulated granules increased numbers of intragranule
membranolipid deposits (Fig. 5C) (11.0 deposits per 100 gran-
ules with BFA vs. 2.6 deposits per 100 granules without BFA),
analogous to BFA’s antisecretory effects on granules within
eosinophils. These findings suggest that the agonist-receptor–
elicited secretion of eosinophil granule proteins is likely depen-
dent on the membranotubular network within granules probably
involved in the mobilization and secretion of their contents
(13–15).
Isolated Eosinophil Granules Secrete Cytokines upon IFN- Stimula-
tion. In addition to cationic proteins (e.g., ECP) and hydrolases
(e.g., -hex), eosinophil granules contain diverse cytokines,
chemokines, and growth factors. Differential regulated secretion
of preformed stores of these mediator proteins contributes to the
capacity of eosinophils to modulate immune and other host
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Fig. 3. Extracellular eosinophil granules express IFN- andCCR3 receptors on
their membranes. By flow cytometry of isolated non–membrane-permeabil-
ized granules, granule surfacemembranes expressed extracellular domains of
the IFN-R  chain (A) and the CCR3 receptor for eotaxin (B) but not the
nonligand (carboxy)-terminal intracellular domain of CCR3 (C). Shaded histo-
grams and solid lines represent staining with control Ab and mAb or pAb-
specific Abs, respectively. Data are from one experiment, representative of
three.
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Fig. 4. IFN-– and eotaxin-elicited ECP secretion by cell-free granules is
mediated by intragranular signaling pathways. Pretreatment of eosinophil
isolated granuleswith indicated concentrations of genistein, a tyrosine kinase
inhibitor (A), SB203580 and SB 202190, both p38 MAPK inhibitors (B), and
calphostin C, a PKC inhibitor (C), with each inhibited ECP secretion elicited by
IFN-. (D) PI3K inhibitor, LY294002, did not inhibit ECP secretion elicited by
IFN-. Eotaxin-induced ECP secretionwas inhibited by pertussis toxin (PTX) (E),
SB203580 and SB 202190 (F), calphostin C (G), and LY294002 (H). Eosinophil
granuleswere pretreatedwith inhibitors for 15min and stimulatedwith IFN-
(200 ng/ml) or eotaxin (100 ng/ml) for 1 h. Secreted ECP levels, means of
duplicates SD, are ECP levels from stimulatedgranulesminus ECP levels from
unstimulated granules as assayed by ELISA. Data, one experiment represen-
tative of three, were analyzed by one-wayANOVA, followed by theNewman-
Keuls test.  and * represent P  0.05 compared with nonstimulated and
cytokine/chemokine-stimulated granules, respectively. (I) Isolated granules
contain PKC and p-38MAPK. (J) Eotaxin (100 ng/ml, 1min) induced phosphor-
ylation of p-38 MAPK on granules. t, total; p, phosphorylated; NS, not stim-
ulated; Eot, eotaxin-stimulated. (K) IFN- (200 ng/ml, 5 min) induced tyrosine
phosphorylation of a granule protein, and genistein (100 M) inhibited
phosphorylation. Loading controls were blotted for granule MPB.
pp tyr, phosphorylated tyrosine residues; NS, not stimulated; IFN, IFN-–
stimulated; Gen, genistein.
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responses (4). As for granules within intact eosinophils, extra-
cellular eosinophil granules can be sources of secreted eosino-
phil-derived cytokines. IFN- dose dependently stimulated se-
cretion of IL-4 and IL-6 but not IL-13 (Fig. 6) and not IL-8,
IL-10, or IL-12 (p70) from isolated granules. Thus, agonist-
dependent processes mediating eosinophil cytokine secretion by
cell-free granules can be selective, as demonstrated with intact
eosinophils (4, 20, 21), providing novel insights into the potential
regulated capabilities of eosinophil granules, when released
extracellularly, to be variably responsive to cytokine, chemokine,
and other agonists in differentially secreting their granule-stored
proteins.
Discussion
Although eosinophils, like other granule-bearing leukocytes,
have been recognized for their capacities to release granule-
derived proteins fromwithin leukocytes, our findings are notable
for several reasons. First, cytoplasmic granules of eosinophils,
the quantitatively predominant and distinguishing intracellular
organelles within these leukocytes, have evolved in a fashion that
uniquely enables these organelles also to function extracellularly
as secretion-competent structures responsive to receptor-
mediated agonists. Granules not only express functional recep-
tors on their surface membranes but couple these receptors to
intragranular signaling and intragranular membranotubular net-
work-based secretion responses.
Second, the topology of receptors expressed on granule
membranes, by which nominally extracellular ligand-binding
receptor domains are displayed externally on granule mem-
branes, raises the possibility that such receptors expressed on
intracellular granules might be indicative of roles of cytokines
and chemokines as intracellular regulators of granule secretion.
Widely abundant GPCRs have traditionally been considered to
transduce signals at the plasma membrane (22) and, more
recently, at nuclear membranes (23). Although a cell-permeant
lipid, estrogen, has signaled through an endoplasmic reticulum–
basedGPCR (24), other nonnuclear intracellular organellar sites
of localization and function for GPCRs have not been identified.
In response to extracellular eotaxin, which is not cell permeable,
CCR3 undergoes ligand-induced internalization from the eosin-
ophil plasma membrane (25). That CCR3 might mediate ligand-
initiated signaling intracellularly has not been suggested, al-
though we previously documented CCR3 protein localization at
isolated eosinophil granules (13). Our current findings recognize
an intracellular localization for a functional GPCR, CCR3, on
eosinophil granule membranes. Limited prior experiments indi-
cated that IFN- can signal intracellularly, but sites of such
signaling, other than potentially at the nucleus for IFN- (26)
after receptor-mediated endocytosis, have not been identified.
Thus, localization of functional IFN-R to eosinophil granule
membranes identifies a subcellular localization for this ligand-
responsive receptor. Recognition that structurally distinct het-
erodimeric IFN-Rs and heptahelical CCR3 GPCRs are ex-
pressed on eosinophil granule membranes and are functional in
mediating cytokine- and chemokine-elicited granule-derived
secretion, extracellularly and potentially intracellularly, extends
our understanding of the function of these receptors on the
membranes of intracellular organelles.
Finally, although cytolytic release of intact eosinophil granules
into tissues is well documented (7–12) but of heretofore ill-
understood consequence, the responsiveness of cytolytically
released, extracellular, fully secretion-competent granules ex-
pands the capacities of eosinophils to contribute to modulating
host and immune responses (1, 2, 27). Because eosinophil
granules have ultrastructurally unique cores and distinct cationic
protein content that can be detected extracellularly by EM, light
microscopy, and immunofluorescence microscopy (7–9, 28),
there may be a detection bias in recognizing extracellular
granules of eosinophils in comparison to granules of other
leukocytes. Intact extracellular granules from other leukocytes
have rarely been sought. In one study that enumerated both free
eosinophil and neutrophil granules, free anti-elastase–staining
neutrophil granules were found in tissues of subjects with chronic
rhinosinusitis but much less commonly than free MBP-positive
eosinophil granules (28). Isolated mast cell granules also have
exhibited ligand-elicited ion fluxes (29). Whether granules of
other leukocytes may likewise express chemokine or cytokine
receptors has not been evaluated, although CCR3 has been
demonstrated on intracellular mast cell granules (30) and IL-10
receptors on neutrophil granules (31). Potential capacities of
granules from other leukocytic cells (e.g., neutrophils, mast cells,
NK cells) to likewise function extracellularly remain to be
assessed. Nevertheless, for eosinophils that undergo cytolysis
and granule extrusion in tissues, the liberated extracellular
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Fig. 5. BFA inhibits ECP secretion from IFN-– (A) and eotaxin- (B) stimulated
eosinophil granules. Secreted ECP levels, means of duplicates  SD, are ECP
levels from stimulated granules minus ECP levels from unstimulated granules,
as assayed after 1 h by ELISA. Data, one experiment representative of three,
were analyzed by one-way ANOVA, followed by the Newman-Keuls test. 
and * represent P  0.05 compared with nonstimulated and cytokine/
chemokine-stimulated granules, respectively. (C) BFA promotes the collapse
ofmembranotubular networkswithingranules formingelectron-densemem-
branolipid deposits (arrows, inset). (Scale bar: 200 nm.) Data are from one
experiment, representative of three.
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Fig. 6. Isolated eosinophil granule cytokine secretion upon IFN- stimula-
tion. IFN- dose dependently induced release of IL-4 and IL-6 but not IL-13
after 1 h. Cytokine levels in unstimulated samples were undetectable. Open,
closed, and hatched columns represent stimulation with 100, 200, and 400
ng/ml IFN-, respectively. Data represent the means of duplicates  SD.
Results, one experiment representative of three, were analyzed by one-way
ANOVA, followed by the Newman-Keuls test. *P  0.05 compared with
nonstimulated granules.
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granules, with their rich content of preformed cytokines and
cationic proteins, may function as cluster-bombs in continuing to
exhibit ‘‘postmortem’’ agonist-specific and differential secretion
of eosinophil granule-derived proteins.
Methods
Eosinophil Purification and Subcellular Fractionation. Eosinophils were ob-
tained from the blood of healthy and atopic donors by previously described
methods (13) with modifications that included collecting blood with pH
neutral sodium citrate buffer (100mM, pH7.4) andnot using erythrocyte lysis.
Experiments were approved by the Beth Israel Deaconess Medical Center
Committee on Clinical Investigation, and informed consent was obtained
fromall subjects. For subcellular fractionation, eosinophils (10–30 106)were
resuspended in disrupting buffer (5) supplemented with 5 g/ml DTT and
subjected to nitrogen cavitation (Parr) (600 psi, 10 min). Postnuclear super-
natants, recovered after centrifugation (400  g, 10 min), were ultracentri-
fuged (100,000  g, 1 h at 4 °C) in linear isotonic Optiprep (Axis-Shield)
gradients (0%–45% in disrupting buffer without protease inhibitors).
Stimulation of Isolated Eosinophil Granules. Subcellular fractions containing
isolated granules were mixed with RPMI plus 0.1% OVA (Sigma), followed by
centrifugation (2,500g, 10min). Pelleted granules, resuspended in 250l of
the same medium, were incubated with IFN- (Biosource International) or
eotaxin (R&D Systems). Treatments with BFA (Biomol), calphostin C (Sigma),
genistein (Sigma), LY294002 (Biomol), SB203580 (Calbiochem), SB202190 (Cal-
biochem), and pertussis toxin (Sigma)were performed for 15min before IFN-
or eotaxin stimulation for 1 h at 37 °C. Inhibitors were diluted in DMSO at a
final concentration 0.01%, which had no effect on granule secretion. TEM
studies were performed on granules treatedwith andwithout BFA for 15min
before IFN- addition.
Granule Isolation Following Eosinophil Cytolytic Degranulation. Plasma-coated
beads were made as previously described (32) with modifications. Briefly,
Sepharose 6B beads (Amersham-Amersham Pharmacia) were incubated with
10% human plasma plus 4.5 g/ml cobra venom factor (Complement Tech-
nologies) for 15min at 37 °C. Eosinophils (5 106 eosinophils per 1.2ml) were
mixed with 500 l plasma-coated beads and incubated for 50 min at 37 °C.
Granules released by cytolysis (19, 32) were recovered in supernatants.
Assays of Eosinophil Granule and Granule-Secreted Proteins. EPO activity was
measured by a colorimetric assay (33) in subcellular fractions and in eosinophil
granule supernatants. For -hex activity, 50-l samples were incubated with
50l substrate solution [1mM4-methylumbelliferylN-acetyl--D-glucosamin-
ide (Sigma) in 0.2M citrate buffer, pH 4.5, plus 0.1% Triton X-100] at 37 °C for
2 h. Reactions were terminated by addition of 100 l of 1 M Tris (pH 8), and
fluorescence (excitation, 360 nm; emission, 460 nm) was measured in a Cyt-
oFluor 2350 plate reader (Millipore).
ECP levels in supernatants of eosinophil granules and sonicated- or cell
extraction buffer– (FNN0011; Biosource) disrupted granules were quantified
by ECP ELISA kits (Medical & Biological Labs). Stimulated ECP secretion rep-
resents ECP levels from stimulated samples minus ECP levels from unstimu-
lated samples.
Cytokines, IL-4, IL-8, IL-6, IL-10, IFN-, IL-13, and IL-12 (p-70)werequantified
using multiplex assays (Bio-Rad Laboratories, Inc.).
Flow Cytometry of Eosinophil Granules. Isolated granules were incubated
either with primary FITC-conjugated Ab (45 min) or primary (1 h) and then
FITC-conjugated secondary (15 min) Abs on ice in the absence of granule
fixation. After staining, granules were fixed in buffer containing 2% parafor-
maldehyde without methanol (Electron Microscopy Sciences) for 5 min. For
intragranular staining, isolated granules were fixed for 5 min in 2% parafor-
maldehyde and permeabilized for 5 min on ice with 0.1% saponin before
incubation with primary (1 h) and secondary (15 min) Abs. Control or nonim-
mune Abs were included for all. Analyses were performed on a FACScan with
CELLQUEST software (BD Biosciences).
For nonpermeabilized granules, rabbit anti-human LAMP-2 Ab (H-207, 5
g/ml; SantaCruzBiotechnology) andmouseanti-humanCD63 (LAMP-3)mAb
(clone H5C6, 20 g/ml; BD PharMingen) were used in parallel with respective
control nonimmune IgGs. Anti-rabbit and anti-mouse FITC-conjugated Abs,
respectively, were secondary Abs (1:100; Jackson ImmunoResearch). Hamster
anti-human IFN-R (clone 2E2, 5 g/ml; Santa Cruz Biotechnology), rat
anti-human CCR3 (clone 61828.11, 5 g/ml; R&D), and mouse anti-human
MHC class I (HLA-ABC, clone G46–2.6, 14 g/ml; BD PharMingen) FITC-
conjugated mAbs, each directed at extracellular domains, were used with
FITC-conjugated IgG control mAbs. Goat Ab generated against a peptide in
the intracellular carboxyl terminus of human CCR3 (5 g/ml, C20; Santa Cruz
Biotechnology) was used with a control nonimmune goat IgG and anti-goat
FITC-conjugated secondary Ab (1:100; Jackson ImmunoResearch). On perme-
abilized granules, mouse anti-human MBP mAb (5 g/ml, clone AHE-2; BD
PharMingen) and an isotype mAb were used, and the secondary Ab was an
FITC-conjugated goat anti-mouse Ab (1:100; Jackson ImmunoResearch).
Western Blotting. Granules were lysed in a 0.5% hexadecyl trimethylammo-
nium bromide (Sigma) Tris buffer (10 mM, pH 7.4) containing 100 mMNaCl, 1
mM EDTA, 1 mM EGTA, 1 mMNaF, 20 mMNa4P2O7, 2 mMNa3VO4, 1% Triton
X-100, 10% glycerol, 1 mM PMSF, and protease inhibitors mixture (P8340,
1:100; Sigma). For phosphorylation assays, we added phosphatase inhibitor
cocktails 1 and 2 (P2850 and P5726, each at 1:100; Sigma). Pools of lysed
granules from three subcellular fractionations were loaded on 10% Bis-Tris
gels (Invitrogen) under denaturing conditions. Gels were transferred to ni-
trocellulosemembranes (Pierce), blocked overnightwith 5%BSA, and probed
with rabbit anti-phospho-p38 MAPK pAb that detects dually phosphorylated
Thr-180 and Tyr-182 (1:200; Cell Signaling), rabbit anti-human PKC ,, pAb
(1:200; Abcam), and rabbit anti-human p-38 MAPK ,,, pAb (1:500; Cell
Signaling), followedbyanti-rabbit secondaryAb conjugated toHRP (1:15,000;
Jackson ImmunoResearch). A mouse anti-human MBP mAb (1:200, clone
AHE-2; BD PharMingen) and a mouse anti-phosphotyrosine mAb (1:1,000,
clone 4G10; Upstate) were used to detect MBP and tyrosine phosphorylated
residues, respectively, followed by anti-mouse secondary Ab conjugated to
HRP (1:15,000; Jackson ImmunoResearch). Membranes were developed with
West Fento chemiluminescence kits (Pierce).
Activation of AO-Bearing Eosinophil Granules. AO labels acidic lysosomal
eosinophil granules (34). As previously described for amast cell line, activation
of granules leads to the release of monomeric AO at a neutral pH, which
exhibits a spectral shift to green yielding transient green flashes from re-
sponding granules (18). To help ascertain that granules obtained by subcel-
lular fractionation and by eosinophil cytolysis were the organelles responsive
to IFN- and eotaxin agonists, we monitored the responses of AO-labeled
eosinophil granules by fluorescence microscopy. Cell-free granules were
loaded with 3 M AO (10 min, 4 °C) (Sigma), washed, and resuspended in
Ca2/Mg2 containing HBSS (HBSS). Granules were spread on polyL-lysine–
coated slides (5 l per slide) and coverslipped. Stimuli in stock solutions of
IFN- (700 ng/ml) or eotaxin (350 ng/ml) or control HBSSwas introduced in
2-l drops at the edge of the coverslips, enabling stimuli to diffuse under the
coverslip. Responses of AO-stained granules were monitored by fluorescence
microscopy using the FITC band fluorescence filter. To prevent AO quenching
during time-lapse microscopy, three neutral density filters (ND6, ND25, and
ND12) were used during data acquisition. To compensate for the low fluores-
cence signal, the gain of the camera was increased to 100 before each
recording. Fluorescence images were recorded for 5 min (100 frames in total)
and were acquired using a Hamamatsu Orca AG cooled monchrome CCD
camera (Bridgewater) coupled to a BX-62 Olympus microscope (Olympus)
using a UplanApo objective (40  1.35). The microscope, Z-motor drive,
shutters, and camera were controlled by IVision 4.0 for Mac (BioVision Tech-
nology). Acquired frames were further processed into movies with IVision.
Images were pseudocolored to display intensities in AO fluorescence.
TEM of Tissue and Granule Samples. A lesional skin biopsy was obtained with
informed consent from a subject with a hypereosinophilic syndrome, as
approved by the Committee on Clinical Investigation. Granule samples in agar
and skin tissuewere prepared for TEM as before (14, 15). Ten granule samples
from different experiments were analyzed by TEM to ensure granule purity.
For identification and quantification of lipid deposits in BFA- and control-
treated granules, a total of 145 electronmicrographs were randomly taken at
21,000 and analyzed at a final magnification of58,000. Between 419 and
529 granules per condition were evaluated blindly by two observers to enu-
merate membranolipid deposits within BFA- and control-treated granules.
Statistical Analysis. Data were expressed as means of replicates  SD. Results
were analyzed by one-way ANOVA, followed by the Newman-Keuls test. P
values 0.05 were considered significant.
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